Leczenie nawrotowego/opornego szpiczaka plazmocytowego w Polsce w oparciu o program lekowy Ministerstwa Zdrowia w nawiązaniu do zaleceń Europejskiego Towarzystwa Onkologii Klinicznej

Abstract

Although survival of multiple myeloma patients has at least doubled during recent years, most patients eventually relapse. At the time of relapse, the use of alternative drugs to those given upfront is current practice. However, many new options are currently available for the treatment of relapsed multiple myeloma, including recently approved drugs, such as the second- and third-generation proteasome inhibitors (carfilzomib and ixazomib), the second- and third-generation immunomodulatory drugs (lenalidomide and pomalidomide), the monoclonal antibodies (daratumumab and elotuzumab) and the histone deacetylase inhibitor (panobinostat). We here describe new treatment options for relapsed multiple myeloma in Poland based on drugs that can be used as part of the Ministry of Health's drug program in the context of ESMO guidelines.